![Koninklijke Philips N.V. Website](https://cdn.finchat.io/185801.png)
Koninklijke Philips N.V.
ENXTAM-PHIA
Company Overview
Koninklijke Philips N.V. operates as a health technology company in North America and internationally. It operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. The company provides diagnostic imaging solutions, includes magnetic resonance imaging, computed tomography (CT) systems, X-ray systems, and detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; integrated interventional systems; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. It also offers acute patient management solutions; emergency care solutions; sleep and respiratory care solutions; and electronic medical record and care management solutions. In addition, the company provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding and digital parental solutions; and male grooming and beauty products and solutions. It has a strategic collaboration with Ibex Medical Analytics Ltd. to jointly promote the digital pathology and AI solutions to hospitals, health networks, and pathology laboratories worldwide, as well as a strategic partnership agreement with NICO.LAB. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.
Name
Koninklijke Philips N.V.
CEO
Mr. Roy Jakobs
Website
www.philips.com
Sector
Health Care Equipment and Supplies
Year Founded
1891
Profile
Market Cap
€25.52B
EV
€32.01B
Shares Out
934.05M
Revenue
€18.13B
Employees
68,701
Margins
Gross
41.56%
EBITDA
7.58%
Operating
3.54%
Pre-Tax
-1.13%
Net
-2.32%
FCF
8.04%
Returns (5Yr Avg)
ROA
2.27%
ROTA
6.85%
ROE
5.52%
ROCE
4.59%
ROIC
4.2%
Valuation (TTM)
P/E
—
P/B
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
EV/Gross Profit
—
Valuation (NTM)
Price Target
€27.63
P/E
—
PEG
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
Financial Health
Cash
€1,813M
Net Debt
€6,453M
Debt/Equity
0.69
EBIT/Interest
2.21
Growth (CAGR)
Rev 3Yr
0.8%
Rev 5Yr
-0.63%
Rev 10Yr
-1.35%
Dil EPS 3Yr
-26.41%
Dil EPS 5Yr
-19.45%
Dil EPS 10Yr
-8.06%
Rev Fwd 2Yr
3.61%
EBITDA Fwd 2Yr
8.58%
EPS Fwd 2Yr
20.17%
EPS LT Growth Est
17.48%
Dividends
Yield
—
Payout
—
DPS
—
DPS Growth 3Yr
—
DPS Growth 5Yr
—
DPS Growth 10Yr
—
DPS Growth Fwd 2Yr
5.67%